# A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

> **NCT05551936** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Vaishalee Kenkre** · enrollment: 42 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT05551936
- **Lead sponsor:** Vaishalee Kenkre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-26
- **Primary completion:** 2026-05
- **Final completion:** 2027-05
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- Epizyme, Inc.
- University of Wisconsin, Madison

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05551936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05551936, "A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT05551936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*